We are live on ! Find out more
LIMN

Liminatus Pharma
LIMN

15 hedge funds and large institutions have $194K invested in Liminatus Pharma in 2026 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

25% more funds holding

Funds holding: 12 → 15 (+3)

3.58% more ownership

Funds ownership: 1.17% → 4.75% (+3.6%)

0% more capital invested

Capital invested by funds: $193K → $194K (+$318)

Holders
15
Holders Change
+3
Holders Change %
+25%
% of All Funds
0.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
5
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$323K
2
CCA
Cygnus Capital Advisors
Georgia
+$187K
3
Jane Street
Jane Street
New York
+$38K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$28.1K
5
UBS Group
UBS Group
Switzerland
+$18.8K

Top Sellers

Rank Fund Capital Flow
1
Two Sigma Investments
Two Sigma Investments
New York
-$21.5K
2
TRCT
Tower Research Capital (TRC)
New York
-$712
3
Bank of America
Bank of America
North Carolina
-$27
4
FFA
Farther Finance Advisors
California
-$9
5
BlackRock
BlackRock
New York
-$1
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
1
Citadel Advisors
Florida
$116K +$323K +606,588 +855%
Geode Capital Management
2
Geode Capital Management
Massachusetts
$20.2K +$28.1K +52,732 +81%
Jane Street
3
Jane Street
New York
$12.3K +$38K +71,318 New
UBS Group
4
UBS Group
Switzerland
$9.39K +$18.8K +35,183 +181%
VCM
5
Vanguard Capital Management
Pennsylvania
$8.68K +$26.9K +50,440 New
VPIM
6
Vanguard Personalized Indexing Management
California
$5.97K +$18.5K +34,706 New
VF
7
Virtu Financial
New York
$5K +$14.6K +27,468 New
VFT
8
Vanguard Fiduciary Trust
Pennsylvania
$3.95K +$12.3K +22,984 New
TSS
9
Two Sigma Securities
New York
$3.79K +$5.42K +10,164 +86%
State Street
10
State Street
Massachusetts
$3.27K – – –
BlackRock
11
BlackRock
New York
$2.28K -$1 -1 -0%
TRCT
12
Tower Research Capital (TRC)
New York
$1.3K -$712 -1,336 -15%
Citigroup
13
Citigroup
New York
$1.16K +$3.61K +6,768 +676,800%
CCA
14
Cygnus Capital Advisors
Georgia
$60 +$187K +350,000 New
FFA
15
Farther Finance Advisors
California
$2 -$9 -17 -55%
Two Sigma Investments
16
Two Sigma Investments
New York
– -$21.5K -35,284 Closed
Bank of America
17
Bank of America
North Carolina
– -$27 -44 Closed

LIMN Hedge Fund Activity: Q1 2026 in Review

15 of the 8,131 institutional investors tracked by Wall St. Rank reported a position in Liminatus Pharma (LIMN) for Q1 2026, worth a combined $194K — up 0.16% from $193K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new LIMN positions and 2 closed out — a net gain of 4 holders — while 5 added to existing stakes and 3 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $323K. The largest seller was Two Sigma Investments, exiting entirely with an estimated $21.5K sold.

  • 15 institutional investors held Liminatus Pharma (LIMN) as of Q1 2026, up from 12 in Q4 2025.
  • Funds reported $194K of Liminatus Pharma stock for Q1 2026, up 0.16% quarter-over-quarter.
  • 6 funds opened new Liminatus Pharma positions in Q1 2026 and 2 closed out, a net change of +4 holders.
  • The largest Liminatus Pharma buyer in Q1 2026 was Citadel Advisors, an estimated $323K added.
  • The largest Liminatus Pharma seller in Q1 2026 was Two Sigma Investments, an estimated $21.5K sold.

Based on aggregated 13F filings for Q1 2026.